{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:07:11Z","timestamp":1789470431432,"version":"build-2803163510"},"reference-count":98,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Inflammatory bowel diseases (IBDs), particularly Crohn\u2019s disease (CD) and ulcerative colitis (UC), are chronic disorders that affect not only the gastrointestinal tract but also other organ systems through extraintestinal manifestations (EIMs). It is estimated that EIM may occur in up to half of all patients, with at least two different EIM present in 20% of cases and preceding the diagnosis of IBD by approximately five months in 26% of cases. The most frequently reported manifestations include dermal lesions, spondyloarthropathy, and hepatobiliary disorders, although ocular involvement is also observed, significantly impairing patients\u2019 daily functioning. Given the profound impact on quality of life (QoL) and the associated diagnostic challenges, this article provides an overview of the epidemiology, pathophysiological mechanisms, and current diagnostic and therapeutic strategies for EIM. Special emphasis is placed on the importance of early recognition and coordinated, multidisciplinary care involving gastroenterology, rheumatology, dermatology, ophthalmology, and other specialties. The roles of genetic, immunological, and environmental factors in the development of these complications are also discussed, along with recent therapeutic advances, including biologics and small molecules. Future directions highlight the need for multicenter studies aimed at improving both prophylactic and therapeutic strategies. This comprehensive narrative review aims to summarize current evidence on the epidemiology, pathophysiology, diagnosis, and treatment of extraintestinal manifestations in IBD, with particular emphasis on their early recognition, multidisciplinary management, and clinical implications. We also discuss emerging therapeutic strategies, screening and referral approaches, and areas requiring further research.<\/jats:p>","DOI":"10.3390\/jcm15187159","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:32:01Z","timestamp":1789468321000},"page":"7159","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is There a Way to Break the Glass Ceiling in the Diagnosis and Treatment of Extraintestinal Manifestations (EIMs) in the Course of Inflammatory Bowel Diseases? A Comprehensive Review of Diagnosis, Pathophysiology, and Treatment of EIM"],"prefix":"10.3390","volume":"15","author":[{"given":"Dominik","family":"Ruta","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-0351","authenticated-orcid":false,"given":"Hubert","family":"\u017bywno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"},{"name":"Doctoral School, Medical University of Warsaw, \u017bwirki i Wigury 61, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Bielski","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-4905","authenticated-orcid":false,"given":"Konrad","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"},{"name":"IBD Clinical and Research Center, ISCARE a.s., 190 00 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Faggiani, I., Fanizza, J., D\u2019Amico, F., Allocca, M., Zilli, A., Parigi, T.L., Barchi, A., Danese, S., and Furfaro, F. (2024). Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081839"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","article-title":"Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease\u2014Epidemiology, genetics, and pathogenesis","volume":"13","author":"Greuter","year":"2019","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.med.51.1.289","article-title":"Role of cytokines in the pathogenesis of inflammatory bowel disease","volume":"51","author":"Papadakis","year":"2000","journal-title":"Annu. Rev. Med."},{"key":"ref_10","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am. J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ni.2847","article-title":"Life at the beginning: Perturbation of the microbiota by antibiotics in early life and its role in health and disease","volume":"15","author":"Zeissig","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.40359","article-title":"Gut Microbiota Perturbations in Reactive Arthritis and Postinfectious Spondyloarthritis","volume":"70","author":"Manasson","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/art.39802","article-title":"Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthritis","volume":"69","author":"Tito","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13059-017-1271-6","article-title":"Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis","volume":"18","author":"Wen","year":"2017","journal-title":"Genome Biol."},{"key":"ref_16","first-page":"270","article-title":"Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches","volume":"21","author":"Alshehri","year":"2021","journal-title":"Bosn. J. Basic. Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.728","article-title":"Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci","volume":"43","author":"Melum","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gutjnl-2012-303956","article-title":"Monogenic diseases associated with intestinal inflammation: Implications for the understanding of inflammatory bowel disease","volume":"62","author":"Uhlig","year":"2013","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0016-5085(00)70209-5","article-title":"Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease","volume":"118","author":"Orchard","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: A multiparametric predictive model","volume":"72","author":"Jacques","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.39681","article-title":"Perturbed Mucosal Immunity and Dysbiosis Accompany Clinical Disease in a Rat Model of Spondyloarthritis","volume":"68","author":"Asquith","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ecco-jcc\/jjv232","article-title":"Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease","volume":"10","author":"Karmiris","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_27","first-page":"2266","article-title":"The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects","volume":"22","author":"Mielants","year":"1995","journal-title":"J. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1572-0241.2006.00456.x","article-title":"Serum immune responses predict rapid disease progression among children with Crohn\u2019s disease: Immune responses predict disease progression","volume":"101","author":"Dubinsky","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11926-996-0038-y","article-title":"Gut inflammation in the spondyloarthropathies","volume":"7","author":"Mielants","year":"2005","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00393-012-1114-5","article-title":"Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications","volume":"72","author":"Varkas","year":"2013","journal-title":"Z. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8","article-title":"Inflammatory bowel disease and spondylarthropathy","volume":"44","author":"Smale","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1055\/s-2002-35938","article-title":"[Magnetic resonance imaging in ankylosing spondylitis (Marie-Struempell-Bechterew disease)]","volume":"174","author":"Bollow","year":"2002","journal-title":"Rofo"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1002\/art.30558","article-title":"Time for a gut check: Evidence for the hypothesis that HLA-B27 predisposes to ankylosing spondylitis by altering the microbiome","volume":"63","author":"Rosenbaum","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/ajg.2012.127","article-title":"The epidemiology of colectomy in ulcerative colitis: Results from a population-based cohort","volume":"107","author":"Targownik","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s00330-013-3074-9","article-title":"Diagnostic value of pelvic enthesitis on MRI of the sacroiliac joints in spondyloarthritis","volume":"24","author":"Jans","year":"2014","journal-title":"Eur. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ueg2.12125","article-title":"The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients","volume":"9","author":"Roth","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.rdc.2012.08.012","article-title":"Pathophysiology and role of the gastrointestinal system in spondyloarthritides","volume":"38","author":"Jacques","year":"2012","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1503\/cmaj.050201","article-title":"Erythema nodosum as a presentation of inflammatory bowel disease","volume":"173","author":"Weinstein","year":"2005","journal-title":"Can. Med. Assoc. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1007\/s10620-020-06424-x","article-title":"Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry","volume":"66","author":"Algaba","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.MIB.0000436959.62286.f9","article-title":"Cutaneous manifestations in patients with inflammatory bowel diseases: Pathophysiology, clinical features, and therapy","volume":"20","author":"Marzano","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1468-3083.2008.02741.x","article-title":"Metastatic Crohn\u2019s disease: A review","volume":"22","author":"Palamaras","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1468-3083.2008.03031.x","article-title":"Psoriasis associated with ulcerative colitis and Crohn\u2019s disease","volume":"23","author":"Cohen","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000341950","article-title":"Treatment of extraintestinal manifestations in inflammatory bowel disease","volume":"86","author":"Lakatos","year":"2012","journal-title":"Digestion"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"15859","DOI":"10.2147\/JIR.S540840","article-title":"Pyoderma Gangrenosum and Inflammatory Bowel Disease: Recent Insights into Epidemiology, Pathogenesis, and Therapeutic Approaches","volume":"18","author":"Downey","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: A retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1590\/abd1806-4841.20175298","article-title":"Sweet\u2019s syndrome associated with Crohn\u2019s disease","volume":"92","author":"Lima","year":"2017","journal-title":"Bras. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12016-017-8617-4","article-title":"Skin Manifestations of Inflammatory Bowel Disease","volume":"53","author":"Greuter","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"V1","DOI":"10.1136\/gut.2004.043372","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"53","author":"Carter","year":"2004","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/CMR.15.1.79-94.2002","article-title":"Clinical aspects and pathophysiology of inflammatory bowel disease","volume":"15","author":"Hendrickson","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-0765.2011.01431.x","article-title":"The association between inflammatory bowel disease and periodontitis among Jordanians: A case-control study","volume":"47","author":"Habashneh","year":"2012","journal-title":"J. Periodontal Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12105-018-0981-8","article-title":"Ulcerated Lesions of the Oral Mucosa: Clinical and Histologic Review","volume":"13","author":"Fitzpatrick","year":"2019","journal-title":"Head. Neck Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2006.03134.x","article-title":"Review article: Altering the natural history of Crohn\u2019s disease--evidence for and against current therapies","volume":"25","author":"Vermeire","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ibd.20584","article-title":"Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: A prospective single-center study","volume":"15","author":"Felekis","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"438402","DOI":"10.1155\/2015\/438402","article-title":"Ocular complications of inflammatory bowel disease","volume":"2015","author":"Mady","year":"2015","journal-title":"Sci. World J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","article-title":"Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab","volume":"67","author":"Laharie","year":"2018","journal-title":"Gut"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00054725-200403000-00012","article-title":"Ocular manifestations of inflammatory bowel disease","volume":"10","author":"Mintz","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archopht.1997.01100150063010","article-title":"Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy","volume":"115","author":"Lyons","year":"1997","journal-title":"Arch. Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.cgh.2019.07.011","article-title":"AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review","volume":"17","author":"Bowlus","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune hepatitis--Update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/j.1572-0241.2008.02052.x","article-title":"Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1572-0241.2006.00943.x","article-title":"Inflammation and coagulation in inflammatory bowel disease: The clot thickens","volume":"102","author":"Danese","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/01.MIB.0000206541.15963.c3","article-title":"Nutritional deficiencies in patients with Crohn\u2019s disease in remission","volume":"12","author":"Filippi","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/ibd.21468","article-title":"Renal manifestations and complications of inflammatory bowel disease","volume":"17","author":"Oikonomou","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Res\u00e1l, T., Farkas, K., and Moln\u00e1r, T. (2021). Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?. Front. Med., 8.","DOI":"10.3389\/fmed.2021.686778"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"(2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ecco-jcc\/jjae049","article-title":"Chronic Kidney Disease in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"18","author":"Zadora","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1378\/chest.06-1074","article-title":"Thoracic manifestations of inflammatory bowel disease","volume":"131","author":"Black","year":"2007","journal-title":"Chest"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s10067-017-3937-6","article-title":"The DETection of Arthritis in Inflammatory boweL diseases (DETAIL) questionnaire: Development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis","volume":"37","author":"Luchetti","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/ecco-jcc\/jjaa096","article-title":"The IBIS-Q [IBd Identification of Spondyloarthritis Questionnaire]: A Novel Tool to Detect Both Axial and Peripheral Arthritis in Inflammatory Bowel Disease Patients","volume":"14","author":"Variola","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/cei.13246","article-title":"Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis","volume":"196","author":"Felice","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s10792-020-01437-x","article-title":"The ocular manifestations in IBD screening (OMIS) questionnaire: Pilot study on detection of ocular involvement in inflammatory bowel diseases","volume":"40","author":"Giuffrida","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"jjaf100","DOI":"10.1093\/ecco-jcc\/jjaf100","article-title":"Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn\u2019s disease: Results from the phase 3 VIVID-1 study","volume":"19","author":"Regueiro","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00054725-199905000-00008","article-title":"Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety","volume":"5","author":"Sandborn","year":"1999","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA","volume":"61","author":"Lucci","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e002280","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: Results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"8","author":"Deodhar","year":"2022","journal-title":"RMD Open"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"438","DOI":"10.23736\/S0026-4806.23.08867-5","article-title":"Considering a Janus kinase inhibitor in patients with concomitant ulcerative colitis and hidradenitis suppurativa\/acne inversa: Is it really a gamble? Hints from a case report","volume":"116","author":"Pellegrino","year":"2025","journal-title":"Minerva Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious Uveitis: A study of 88 patients with long-term follow-up","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1872-034X.2009.00527.x","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: Meta-analysis of randomized controlled trials","volume":"39","author":"Shi","year":"2009","journal-title":"Hepatol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG Clinical Guideline: Primary Sclerosing Cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"goag079","DOI":"10.1093\/gastro\/goag079","article-title":"Real-world data on clinical response to inflammatory bowel disease biological treatments in patients with concurrent primary sclerosing cholangitis: A case-control study","volume":"14","author":"Tosse","year":"2026","journal-title":"Gastroenterol. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2015). EASL Clinical Practice Guidelines: Autoimmune hepatitis. J. Hepatol., 63, 971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","article-title":"Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: The SPIRIT Consensus From the IOIBD","volume":"160","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.3748\/wjg.v29.i41.5668","article-title":"Inflammatory bowel diseases patients suffer from significant low levels and barriers to physical activity: The \u201cBE-FIT-IBD\u201d study","volume":"29","author":"Gravina","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"502203","DOI":"10.1016\/j.gastrohep.2024.502203","article-title":"Profiling the patient with inflammatory bowel disease in the relationship between physical activity and partner\/social network status: A post hoc patient-tailored analysis of the \u201cBE-FIT-IBD\u201d study","volume":"48","author":"Gravina","year":"2025","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/gastroent15040067","article-title":"Too Many Couch Potatoes Among Middle-Aged Inflammatory Bowel Disease Patients: Findings from the \u201cBE-FIT-IBD-2\u201d Study","volume":"15","author":"Gravina","year":"2024","journal-title":"Gastroenterol. Insights"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"6","author":"Barberio","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1136\/gutjnl-2021-325985","article-title":"Bidirectional brain-gut axis effects influence mood and prognosis in IBD: A systematic review and meta-analysis","volume":"71","author":"Fairbrass","year":"2022","journal-title":"Gut"},{"key":"ref_96","first-page":"Cd006913","article-title":"Psychological interventions for treatment of inflammatory bowel disease","volume":"4","author":"Neuser","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Pellegrino, R., De Costanzo, I., Imperio, G., Izzo, M., Landa, F., Durante, A., Federico, A., and Gravina, A.G. (2025). Work Absenteeism in Inflammatory Bowel Disease Patients Related to Patient-Reported Anxiety Levels and Disease Activity: The IBD-GO-WORK Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14134410"},{"key":"ref_98","first-page":"142","article-title":"A proposed comprehensive model of care for inflammatory bowel disease in Poland","volume":"20","author":"Rydzewska","year":"2025","journal-title":"Prz. Gastroenterol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7159\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:49:09Z","timestamp":1789469349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":98,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187159"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187159","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}